Find therapies in clinical trials near you

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

Study of TAK-280, Tocilizumab, and Siltuximab for Patients with Advanced or Metastatic Cancer

Study of TAK-280, Tocilizumab, and Siltuximab for Patients with Advanced or Metastatic Cancer

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments

Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments